Table 2

Risk estimates for validated metabolite associations with incident gallstone disease

HMDB IDMetaboliteNHS and NHS II
(OR (95% CI, PFDR))		WHI
(OR (95% CI, PFDR))		HPFS
(OR (95% CI, PFDR))
Positive
HMDB0005433C50:3 TAG1.16 (1.09–1.23, 0.0001)*1.33 (1.11–1.60, 0.045)*1.19 (1.01–1.41, 0.198)
HMDB0005377C50:2 TAG1.12 (1.06–1.19, 0.001)*1.37 (1.14–1.64, 0.045)*1.20 (1.03–1.41, 0.178)
HMDB0005432C48:3 TAG1.12 (1.06–1.19, 0.0007)*1.34 (1.11–1.60, 0.045)*1.23 (1.06–1.43, 0.146)
HMDB0005376C48:2 TAG1.11 (1.05–1.18, 0.002)*1.34 (1.12–1.61, 0.045)*1.19 (1.02–1.40, 0.195)
HMDB0007103C34:2 DAG1.11 (1.05–1.17, 0.003)*1.30 (1.09–1.55, 0.045)*1.21 (1.05–1.40, 0.146)
HMDB0010419C46:2 TAG1.10 (1.04–1.16, 0.006)*1.31 (1.10–1.57, 0.045)*1.19 (1.03–1.38, 0.178)
HMDB0005359C48:1 TAG1.09 (1.03–1.15, 0.012)*1.32 (1.10–1.58, 0.045)*1.19 (1.02–1.39, 0.178)
HMDB0007099C32:1 DAG1.09 (1.03–1.15, 0.011)*1.37 (1.14–1.65, 0.045)*1.19 (1.03–1.37, 0.178)
HMDB0010412C46:1 TAG1.09 (1.03–1.15, 0.012)*1.31 (1.09–1.57, 0.045)*1.17 (1.01–1.36, 0.225)
Negative
HMDB0011394C40:7 PE plasmalogen0.87 (0.82–0.92, 0.0001)*0.71 (0.60–0.85, 0.010)*1.08 (0.92–1.26, 0.753)
HMDB0006733C22:6 CE0.87 (0.82–0.93, 0.0003)*0.76 (0.64–0.90, 0.045)*1.00 (0.84–1.19, 0.995)
HMDB0011420C38:7 PE plasmalogen0.89 (0.83–0.94, 0.001)*0.77 (0.65–0.91, 0.045)*1.05 (0.89–1.24, 0.932)
HMDB0011244C36:3 PC plasmalogen0.91 (0.85–0.96, 0.008)*0.77 (0.65–0.91, 0.045)*0.87 (0.73–1.04, 0.445)
HMDB0011442C36:4 PE plasmalogen0.91 (0.86–0.96, 0.008)*0.79 (0.68–0.93, 0.045)*1.02 (0.87–1.20, 0.990)
HMDB0011387C38:6 PE plasmalogen0.91 (0.86–0.96, 0.008)*0.77 (0.65–0.91, 0.045)*0.99 (0.84–1.16, 0.995)
HMDB0011343C34:3 PE plasmalogen0.91 (0.86–0.96, 0.006)*0.74 (0.63–0.86, 0.010)*1.08 (0.92–1.26, 0.730)
HMDB0011410C36:5 PE plasmalogen0.92 (0.87–0.98, 0.023)*0.77 (0.65–0.91, 0.045)*1.01 (0.86–1.18, 0.995)

  • *Estimates for covariates adjusted for in the multivariable model are detailed in online supplemental table 3.

  • CE, cholesterol ester; DAG, diacylglycerol; PC, phosphatidylcholine; PE, phosphatidylethanolamine; TAG, triacylglycerol.